Crystal Adam’s Tango Therapeutics Sale: Routine Plan or Market Insight?
Crystal Adam’s March 2026 sale of 20,251 Tango shares is a routine Rule 10b‑5 move amid strong trial data and a new Erasca partnership—no red flags yet.
4 minutes to read
Tango Therapeutics Inc
Crystal Adam’s 54,345‑Share Sale Signals Tango Therapeutics’ Long‑Term Growth Strategy
Crystal Adam’s 54,345‑share sale at $12.77 shows disciplined liquidity planning, boosting Tango’s options exposure ahead of Q4 earnings and future growth.
4 minutes to read
Insider Buys at Tango Therapeutics Signal Confidence in Rare‑Disease Pipeline
Insider buys at Tango Therapeutics signal confidence in its rare‑disease pipeline, highlighting strategic alliances, orphan‑drug advantages and a bullish outlook for investors.
4 minutes to read